141 related articles for article (PubMed ID: 758043)
1. Testosterone metabolism in patients with advanced carcinoma of the prostate: a comparative in vivo study of the effects of oestrogen and antiprolactin.
Jacobi GH; Sinterhauf K; Kurth KH; Altwein JE
Urol Res; 1978; 6(3):159-65. PubMed ID: 758043
[TBL] [Abstract][Full Text] [Related]
2. The effects of chlorotrianisene (Tace) of kinetics of 3H-testosterone metabolism in patients with carcinoma of the prostate.
Baba S; Janetschek G; Pollow K; Hahn K; Jacobi GH
Br J Urol; 1982 Aug; 54(4):393-8. PubMed ID: 6810984
[TBL] [Abstract][Full Text] [Related]
3. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy.
Harper ME; Peeling WB; Cowley T; Brownsey BG; Phillips ME; Groom G; Fahmy DR; Griffiths K
Acta Endocrinol (Copenh); 1976 Feb; 81(2):409-26. PubMed ID: 946155
[TBL] [Abstract][Full Text] [Related]
4. Some effects of treatment with ethinyl oestradiol with or without polyoestradiol phosphate in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol; 1986; 20(3):193-6. PubMed ID: 3097813
[TBL] [Abstract][Full Text] [Related]
5. Bromocriptine and prostatic carcinoma: plasma kinetics, production and tissue uptake of 3H-testosterone in vivo.
Jacobi GH; Sinterhauf K; Kurth KH; Altwein JE
J Urol; 1978 Feb; 119(2):240-3. PubMed ID: 633485
[TBL] [Abstract][Full Text] [Related]
6. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
[TBL] [Abstract][Full Text] [Related]
7. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
[TBL] [Abstract][Full Text] [Related]
8. Prostatic carcinoma: plasma kinetics and intraprostatic metabolism of testosterone in low-dose estrogen-treated patients in vivo.
Jacobi GH; Sinterhauf K; Altwein JE
Urology; 1978 Sep; 12(3):359-64. PubMed ID: 706029
[TBL] [Abstract][Full Text] [Related]
9. Effects of oestrogen treatment on serum gonadotrophin bioactivity, immunoreactivity and isohormone distribution, and on immunoreactive inhibin levels, in prostatic cancer patients.
Matikainen T; Haavisto AM; Permi J; de Kretser D; Huhtaniemi I
Clin Endocrinol (Oxf); 1994 Jun; 40(6):743-50. PubMed ID: 8033364
[TBL] [Abstract][Full Text] [Related]
10. Testicular endocrine function after withdrawal of oestrogen treatment in patients with carcinoma of the prostate.
Tomić R; Bergman B; Damber JE
Br J Urol; 1983 Feb; 55(1):42-7. PubMed ID: 6402048
[TBL] [Abstract][Full Text] [Related]
11. Effect of a new LH-RH analogue (D-Ser(TBU)6-EA10-LH-RH) on gonadotrophin and gonadal steroid secretion in men.
Wiegelmann W; Solbach HG; Kley HK; Nieschlag E; Rudorff KH; Krüskemper HL
Horm Res; 1976; 7(1):1-10. PubMed ID: 793974
[TBL] [Abstract][Full Text] [Related]
12. Hypogonadism, galactorrhoea and hyper-prolactinaemia: Evaluation of pituitary gonadotrophins reserve before and under bromocriptine.
Asfour M; L'Hermite M; Hedouin-Quincampoix M; Fossati P
Acta Endocrinol (Copenh); 1977 Apr; 84(4):738-49. PubMed ID: 322432
[TBL] [Abstract][Full Text] [Related]
13. Parlodel treatment of patients with pathospermia.
Szöllösi J; Szilágyi I; Sas M
Int Urol Nephrol; 1982; 14(3):307-12. PubMed ID: 6819245
[TBL] [Abstract][Full Text] [Related]
14. [Bromocriptine for palliation of advanced prostatic carcinoma. Experimental and clinical profile of a drug (author's' transl)].
Jacobi GH; Altwein JE
Urol Int; 1979; 34(4):266-90. PubMed ID: 89747
[TBL] [Abstract][Full Text] [Related]
15. The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin.
Jeromin L
Int Urol Nephrol; 1982; 14(1):51-6. PubMed ID: 6889585
[TBL] [Abstract][Full Text] [Related]
16. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
Robyn C; Vekemans M
Acta Endocrinol (Copenh); 1976 Sep; 83(1):9-14. PubMed ID: 989226
[TBL] [Abstract][Full Text] [Related]
17. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis.
Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Chang LS
BJU Int; 2002 May; 89(7):710-3. PubMed ID: 11966629
[TBL] [Abstract][Full Text] [Related]
18. The effect of antiestrogen, antiandrogen, and the prolactin inhibitor 2 bromo-alpha-ergocriptine on the stromal tissue of human benign prostatic hyperplasia. Correlation of stereological data and plasma hormones.
Bartsch G; Oberholzer M; Rohr HP
Invest Urol; 1981 Jan; 18(4):308-12. PubMed ID: 6161105
[TBL] [Abstract][Full Text] [Related]
19. [Testosterone, FSH and LH level in the serum of patients with prostatic neoplasms, treated with female hormones].
Weidner W; Krause W; Pust R; Engstfeld J; Rothauge CF
Helv Chir Acta; 1978 Jul; 45(3):287-90. PubMed ID: 701064
[TBL] [Abstract][Full Text] [Related]
20. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
